Q&A Genmab 2019-08-20

	20/8 16:57 af Jan Van de Winkel	We only have information from the filing by Horizon Pharma in early July for a BLA, and have not heard feedback from the FDA.
	20/8 16:57 af Bulder	Will the Griffin combo make people forgo transplant?
	20/8 16:58 af Jan Van de Winkel	It is too early to speculate on the dynamics of the future frontline treatment landscape.
	20/8 16:58 af Bulder	What do we know about long term toxicities of dara?
	20/8 16:59 af Jan Van de Winkel	DARA has one of the cleanest safety profiles of all cancer drugs known to date. We continously monitor safety of this medicine.
	20/8 16:59 af Bulder	Are there clear differences between dara and isatuxumab besides the sc/IV infusion?
	20/8 17:00 af Jan Van de Winkel	Preclinically the two ABs have very different mechanisms of action (DARA has a far broader MoA than Isatuximab)...
	20/8 17:01 af Jan Van de Winkel	Another clear difference is that DARA is a fully human antibody, whereas Isatuximab is a humanized antibody, which may be less optimal for long term use in patients.
	20/8 17:02 af Solsen	Mr Winkel Hence DR5xDR5 are your own drug can you tell how many pts there is recruitet. And are the drug still a candidate for partnering. If positive then when can we expect this happen.
	20/8 17:03 af Jan Van de Winkel	We are currently dose escalating HexaBody DR5/DR5 and expect to present a status update of the first clinical study in 2019.
	20/8 17:03 af Solsen	Mr Winkel Now more pts have been testet in CD20xCD3 trial can you tell us how the silenced arm er doing ?
	20/8 17:04 af Jan Van de Winkel	We are still dose escalating DuoBody CD3xCD20 and have already observed signs of biologic activity. Hopefully, we can present early data from the first clinical trial at a medical conference in 2019.
	20/8 17:04 af Solsen	Mr Winkel. The hexa-CD38 deal with Janssens having a decision point with PoC. Could you put a timeline to that ?
	20/8 17:06 af Jan Van de Winkel	The deal structure on HexaBody CD38 dictates that Janssen can await the results of two clinical studies, one in MM and one in DLBCL before exercising their option to further develop this exciting asset...
	20/8 17:06 af Jan Van de Winkel	However, Janssen does not have to wait until all the data is collected and could exercise their option after only a few patients treated if the data is striking...
	20/8 17:07 af Jan Van de Winkel	Timing is thus unclear. We will update the market once HexaBody CD38 is ready for clinical evaluation...
	20/8 17:07 af Jan Van de Winkel	We hope to soon present the very strong preclinical data with HexaBody CD38 at a scientific conference.
	20/8 17:08 af Bulder	Can we expect a company announcement with top line Asclepios data before publication of the Ectrims abstract on Sept 11?
	20/8 17:09 af Jan Van de Winkel	You can expect a company announcement from Genmab once the data from the ASCLEIPIOS stud
	20/8 17:09 af Jan Van de Winkel	You can expect a company announcement from Genmab once the data from the ASCLEPIOS studies become available.
	20/8 17:09 af Bulder	Any news on the potential revival of sc dara in solid tumors, that was mentioned on JnJ Pharma Day in May?
	20/8 17:09 af Jan Van de Winkel	No further news at this time.
	20/8 17:10 af Solsen	Mr Winkel. Obviously DR5xDR5 have effect in MM and especially in RRMM. Do you have plans for trials in these indications or do any agreement with JNJ hold you from doing that ?
	20/8 17:11 af Jan Van de Winkel	At present we are focusing clinical development of HexaBody DR5/DR5 in solid tumors...

	20/8 17:11 af Jan Van de Winkel	Once the data is available and we have established a safe and effective dose, it is certainly possible to broaden the target base for this molecule.
	20/8 17:12 af Budweis	As an long term investor I will thank you Jan for an amazing journey. What is your long term plan with the US listing? Could it be an idea to be listed 100% in US?
	20/8 17:13 af Jan Van de Winkel	Thank you for the kind notes. We firmly believe that a dual listing is optimal to get a broader investor base. With the succesful US listing, we hope to further raise the profile of Genmab as an antibody innovation powerhouse.
	20/8 17:14 af Helge Larsen/PI-redaktør	And now to the last question.
	20/8 17:14 af Solsen	Mr Winkel You have several times expressed that your goal is to bring Genmab on level with ex Regereron and a value arround $40 bn. Do you belive its in the timeline with your vision period 2025.
	20/8 17:15 af Jan Van de Winkel	We have an ambition to further build Genmab into an iconic biotechnology company, and the prospects have never looked as strong as today. It is not possible to comment on how the market will develop over the coming years...
	20/8 17:16 af Jan Van de Winkel	But we are in excellent position to reach our inspirational 2025 vision, having a strong company with an amzing talent base and a growing income stream and above all the support of loyal intelligent and stimulating investors behind us.
	20/8 17:16 af Helge Larsen/PI-redaktør	Thank You for joining us and thank you for the many fullfilling answers to our questions. We look forward to seeing you back here on ProInvestor.com after Q3 .
	20/8 17:17 af Jan Van de Winkel	You are very welcome. We truly enjoyed this stimulating session and cannot wait for the next one. Thanks.
	20/8 17:17 af Helge Larsen/PI-redaktør	This session have ended.